Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.
The development of cellular resistance to platinum-based chemotherapies is often associated with reduced intracellular platinum concentrations. In some models, this reduction is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface. Given the central role of platinum drugs in the clinic, it is critical to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concentration enough to inhibit the proliferation of cisplatin-resistant cells. Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogues as payloads is a possible strategy to solve this problem. This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China , Beijing 100190, People's Republic of China.
Xue
X
Xue
Matthew D
MD
Hall
Qiang
Q
Zhang
Paul C
PC
Wang
Michael M
MM
Gottesman
Xing-Jie
XJ
Liang
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism*; D002945:Cisplatin / Q000737:chemistry / Q000494:pharmacology*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D051379:Mice; D053758:Nanoparticles; D036103:Nanotechnology; D009944:Organoplatinum Compounds / Q000737:chemistry; D021381:Protein Transport
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C503131:lipoplatin; D002945:Cisplatin